The systemic safety of inhaled corticosteroid therapy: A focus on ciclesonide

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 2, 2006, Pages 149-157

  Meltzer, Eli O ^a   Derendorf, Hartmut ^b  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; CORTICOSTEROID; DEISOBUTYRYLCICLESONIDE; DRUG METABOLITE; FLUTICASONE PROPIONATE; HYDROCORTISONE; PLASMA PROTEIN; TETRACOSACTIDE; UNCLASSIFIED DRUG;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; AREA UNDER THE CURVE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG SAFETY; EVALUATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG FUNCTION; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

EID: 33747711384     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60005-1     Document Type: Review

References (77)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2002.
2. National Institutes of Health. Second Expert Panel on the Management of Asthma: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. Report 97-4051.
3. Adams N, Bestall JM, Jones PW. Inhaled fluticasone at different doses for chronic asthma. Cochrane Database Syst Rev. 2002;(1):CD003534.
4. Adams N, Bestall J, Jones PW. Inhaled fluticasone propionate for chronic asthma. Cochrane Database Syst Rev. 2001;(3): CD003135.
5. O'Connell HI. Review of the unique properties of budesonide. Clin Ther. 2003;25(suppl C):C42-60.
6. Waugh J, Goa KL. Flunisolide HFA. Am J Respir Med. 2002;1:369-372; discussion 373.
7. Jackson LD, Polygenis D, McIvor RA, et al. Comparative efficacy and safely of inhaled corticosteroids in asthma. Can J Clin Pharmacol. 1999;6:26-37.
8. Corren J, Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther. 2003;25:776-798.
9. Jacobson K, Chervinsky P, Noonan M, et al; Azmacort HFA Clinical Study Group. Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with ihe non-CFC propellant HFA-134a in paiients with asthma. Ann Allergy Asthma Immunol. 1999;83:327-333.
10. Welch M, Bernstein D, Gross G, et al; Azmacort HFA Study Group. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Chest. 1999;116:1304-1312.
11. Sheffer AL, LaForce C, Chervinsky P, et al; Fluticasone Propionate Asthma Study Group. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Fam Pract. 1996;42:369-375.
12. Galant SP, van Bavel J, Finn A, et al. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 1999;82:273-280.
13. Molimard M, Martinat Y, Rogeaux Y, et al. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med. 2005;99:770-778.
14. Berend N, Kellett B, Kent N, et al. Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. Respirology. 2001;6:237-246.
15. Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day-(-1)) in patients with asthma. Respir Med. 2001;95:212-220.
16. Kemp JP, Berkowitz, RB, Miller SD, et al. Mometasone furcate administered once daily is as effective as twice-daily administration for treatment of mild-to-modcrate persistent asthma. J. Allergy Clin Immunol. 2000;106:485-492.
17. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000;84:417-424.
18. Tinkelman DG, Bronsky EA, Gross G, et al. Efficacy and safety of budesonide inhalation powder (Pulmicort Turbuhaler) during 52 weeks of treatment in adults and children with persistent asthma. J Asthma. 2003;40:225-236.
19. Terzano C, Allegra L, Barkai L, et al. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur Rev Med Pharmacol Sci. 2001;5:17-24.
20. Fernandes AL, Faresin SM, Amorim MM, et al. Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial. Sao Paulo Med J. 2001;119:169-174.
21. Bisca N, Cernatescu I, Dragomir D, et al. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma. Respir Med. 2003;97(suppl B):S15-20.
22. Hampel F, Lisberg E, Guerin JC. Effectiveness of low doses (50 and 100 microg b.i.d) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma. Study Group. J Asthma. 2000;37:389-398.
23. Roland N, Bhalla R, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213-219.
24. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146-152.
25. Toogood JH. Side effects of inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:705-713.
26. Kelly HW. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112:469-478; quiz 479.
27. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 suppl):S1-S40.
28. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol. 2005;94:15-21;quiz22-13, 79.
29. Hanania N, Chapman K, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98:196-208.
30. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol. 1995;96:157-166.
31. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
32. Doull I, Freezer N, Holgate S. Osteocalcin, growth, and inhaled corticosteroids: a prospective study. Arch Dis Child. 1996;74:497-501.
33. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA. 1998;280:539-543.
34. Allen DB. Systemic effects of inhaled corticosteroids in children. Curr Opin Pediatr. 2004;16:440-444.
35. Bonala SB, Reddy BM, Silverman BA, et al. Bone mineral density in women with asthma on long-term inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2000;85(6 pt 1):495-500.
36. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-1353.
37. Agertoft L, Laulund LW, Harrison LI, et al. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol. 2003;35:192-199.
38. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-1383.
39. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Zig Wiss. 1992;137:161-167.
40. Derendorf H, Mollmann H, Hochhaus G, et al. Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Ther. 1997;35:481-488.
41. Tashkin D. The role of small airway inflammation in asthma. Allergy Asthma Proc. 2002;23:233-242.
42. Chalupa DC, Morrow PE, Oberdorster G, et al. Ultrafine particle deposition in subjects with asthma. Environ Health Perspect. 2004;112:879-882.
43. Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209-1226.
44. Feddah MR, Brown KF, Gipps EM, et al. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci. 2000;3:318-324.
45. Micheletto C, Guerriero M, Tognella S. et al. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma. Respir Med. 2005;99:850-855.
46. Whelan GJ, Blumer JL, Martin RJ, et al. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. J Allergy Clin Immunol. 2005;116:525-530.
47. Thongngarm T, Silkoff PE, Kossack WS, et al. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42:257-263.
48. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91(suppl A):22-28.
49. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 pt 2):S440-S446.
50. Allen DB. Sense and sensitivity: assessing inhaled corticosteroid effects on the hypothalamic-pituitary-adrenal axis. Ann Allergy Asthma Immunol. 2002;89:537-539.
51. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:326-334; quiz 334-325, 404.
52. Dietzel K, Engelstatter R, Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res. 2001;31:91-93.
53. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther. 2004;309:249-258.
54. Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18:390-396.
55. Reynolds NA, Scott LJ. Ciclesonide. Drugs. 2004;64:511-519; discussion 520-511.
56. Nave R, Bethke T, van Marie S, et al. Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinetics. 2004;43:479-486.
57. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003;43:365-378.
58. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosieroid, ciclesonide. Am J Ther. 2005;12:201-209.
59. Adinoff B, Iranmanesh A, Veldhuis J, et al. Disturbances of the stress response: the role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Rex World. 1998;22:67-72.
60. Oelkers W. Adrenal insufficiency. N Engl J Med. 1996;335:1206-1212.
61. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999;282:671-676.
62. Broide J, Soferman R, Kivily S, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosieroids. J Clin Endocrinol Metab. 1995;80:1243-1246.
63. Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma: a dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000;162:2053-2057.
64. Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355:542-545.
65. Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf). 1996;44:151-156.
66. Abdu TA, Elhadd TA, Neary R, et al. Comparison of the low dose short synactlien test (I microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Melab. 1999;84:838-843.
67. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol. 2005;115:940-945.
68. Weinbrenner A, Huneke D, Zsehiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab. 2002;87:2160-2163.
69. Deroni E, van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide und fluticasone propionate on cortisol secretion and airway responsivcness 10 adenosine 5′ monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005;18:328-336.
70. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect HPA-axis function in patients with moderate-to-severe persistent asthma. Chest. 2005;128:1104-1114.
71. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 2005;94:465-472.
72. Casale TB, Nelson HS, Stricker WE, et al. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immnnol. 2001;87:379-385.
73. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320mug for 12 weeks is safe and effective in patients with persistent asthma. Respir Med. 2005;99:1275-1285.
74. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005;60:330-337.
75. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest. 2005;127:851-860.
76. Postma D, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001;17:1083-1088.
77. Rohatagi S, Bye A, Falcoz C, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol. 1996;36:938-941.